Tag: ARK Genomic Revolution ETF

Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC

GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT

‘Buying stuff like it’s going out of fashion’: Biotech M&A on track for best year since pre-Covid

Family office deal-making rebounds in April with healthcare bets

Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion

How CNBC Cures is bringing rare disease stories to a national audience

FDA vaccine head will step down in April after string of controversial decisions

FDA reversals leave investors worrying about the fates of other experimental drugs

FDA official calls UniQure’s gene therapy a ‘failed’ treatment for Huntington’s disease

Three decades into cystic fibrosis fight, Boomer Esiason and his son Gunnar are winning